Orexigen buys back Contrave rights from Takeda

15 March 2016

Orexigen Therapeutics (Nasdaq: OREX) and the US subsidiary of Takeda Pharmaceutical (TYO: 4502) have agreed to terminate their collaboration agreement for obesity drug Contrave (naltrexone HCl/bupropion HCl).

Contrave is the market leading national branded prescription treatment option for certain overweight and obese adults for chronic weight management, said the US firm, which saw its shares leap as much as 41.4% to $0.70 in pre-market trading this morning.

Completion of the transaction is subject to the parties' receipt of clearance under the Hart-Scott-Rodino Antitrust Improvement Act. Following closing, they have agreed to a 180-day transition period, during which time Takeda will continue to commercialize Contrave in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK